Harout Semerjian - 06 Aug 2021 Form 3 Insider Report for GLYCOMIMETICS INC (GLYC)

Role
Chief Executive Officer, Director
Signature
/s/ Brian F. Leaf, attorney-in-fact
Issuer symbol
GLYC
Transactions as of
06 Aug 2021
Net transactions value
$0
Form type
3
Filing time
10 Aug 2021, 16:16:34 UTC
Next filing
25 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GLYC No securities beneficially owned 0 06 Aug 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLYC Employee Stock Option (right to buy) 06 Aug 2021 Common Stock 1,098,400 $2.03 Direct F1
holding GLYC Employee Stock Option (right to buy) 06 Aug 2021 Common Stock 549,200 $2.03 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option will vest on August 3, 2022 and the remaining underlying shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.
F2 50% of the shares underlying this option will vest upon FDA approval of the Issuer's product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to the Reporting Person's continued service with the Issuer through the applicable vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney